Prosecution Insights
Last updated: May 29, 2026

Millennium Pharmaceuticals Inc.

6 pending office actions • 4 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Portfolio Summary

6
Total Pending OAs
4
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

6
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (6)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
3
Medium (50%)
0
Easy (0%)
3
Unknown (50%)

Rejection Statute Mix

BucketCases
§103 only2 (33%)
§102 only1 (17%)
No statute on record3 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
83% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
17% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HADDAD, MAHER M 2 50.4% +54.3%
WHITE, DAWANNA SHAR-DAY 1 62.3% +24.5%
PACKARD, BENJAMIN J 1 66.2% +15.8%
SHARMA, YASHITA 1 82.2% +26.2%
PETERS, ALEC JON 1 68.6% +61.7%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17906438 DEVICES AND METHODS FOR TREATING A FISTULA SHARMA, YASHITA 35d overdue

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
18731923 ADMINISTRATION OF AURORA KINASE INHIBITOR AND CHEMOTHERAPEUTIC AGENTS WHITE, DAWANNA SHAR-DAY 98d overdue
16608895 METHOD OF TREATING PEDIATRIC DISORDERS HADDAD, MAHER M 84d overdue
17655541 METHODS FOR THE TREATMENT OF CHRONIC POUCHITIS HADDAD, MAHER M 67d overdue
17604324 ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR COMBINATION THERAPY PETERS, ALEC JON 38d overdue
17906438 DEVICES AND METHODS FOR TREATING A FISTULA SHARMA, YASHITA 35d overdue
17919952 LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF PACKARD, BENJAMIN J 28d overdue

Top Art Units

Art UnitApps
1641 3
1627 1
1612 1
3774 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18731923 ADMINISTRATION OF AURORA KINASE INHIBITOR AND CHEMOTHERAPEUTIC AGENTS WHITE, DAWANNA SHAR-DAY 1627 Other Non-Final OA 98d overdue Pending Jun 03, 2024
17919952 LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF PACKARD, BENJAMIN J 1612 Other Non-Final OA 28d overdue Pending Oct 19, 2022
17906438 DEVICES AND METHODS FOR TREATING A FISTULA SHARMA, YASHITA 3774 §103 Final Rejection 35d overdue Pending Sep 15, 2022
17655541 METHODS FOR THE TREATMENT OF CHRONIC POUCHITIS HADDAD, MAHER M 1641 §102 Non-Final OA 67d overdue Pending Mar 18, 2022
17604324 ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR COMBINATION THERAPY PETERS, ALEC JON 1641 Other Final Rejection 38d overdue Pending Oct 15, 2021
16608895 METHOD OF TREATING PEDIATRIC DISORDERS HADDAD, MAHER M 1641 §103 Non-Final OA 84d overdue Pending Oct 28, 2019

Managing Millennium Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month